Qyuns Therapeutics Enrolls First Subject in Phase 3 Trial of Skin Disease Drug

Qyuns Therapeutics (HKG:2509) enrolled the first subject for its phase 3 clinical trial of QX005N, a treatment for prurigo nodularis, a chronic and inflammatory skin disease, according to a Wednesday

MT NewswiresMay 30 06:22 ET

Changes in Hong Kong stocks | Quanxin Bio-B (02509) rose more than 7% QX005N Tuberous Prurigo Phase III Clinical Trial Successfully Achieved First Patient Enrollment

Quanxin Bio-B (02509) rose more than 7%. As of press release, it rose 6.95% to HK$29.25, with a turnover of HK$2,5592 million.

Zhitong FinanceMay 30 02:21 ET

Zhitong Hong Kong stocks have known for a long time | Pig breeding is fully profitable State Council: Gradually lift restrictions on NEV purchases in various regions

The State Council issued the “2024-2025 Action Plan for Energy Conservation and Carbon Reduction”, which mentions strengthening the regulation of production capacity and output in the building materials industry. Strictly implement the replacement of cement and flat glass production capacity.

Zhitong FinanceMay 29 19:28 ET

Quanxin Bio-B (02509.HK): QX005N Tuberous Prurigo Phase III Clinical Trial Successfully Achieved First Patient Enrollment

On May 29, Ge Longhui | Quanxin Bio-B (02509.HK) announced that on May 29, 2024, the QX005N injection phase III clinical trial (registration number: CTR20241660) independently developed by the company reached the enrollment of the first test subjects. This is the first phase III clinical trial for PN indications carried out by a Chinese company in China. On January 31, 2024, QX005N was included in the list of breakthrough therapeutic varieties by the Drug Evaluation Center of the State Drug Administration. The corresponding indication is PN. This test is an evaluation of the QX00

Gelonghui FinanceMay 29 06:53 ET

China Grants Investigational New Drug Status to Qyuns Therapeutics' Urticaria Treatment

China's medical products administrator granted investigational new drug status to Qyuns Therapeutics' (HKG:2509) QX013N for chronic spontaneous urticaria, a skin condition, according to a Thursday fil

MT NewswiresMay 10 06:04 ET

Quanxin Bio-B (02509.HK) obtained QX013N clinical trial approval for a new drug for the treatment of chronic spontaneous urticaria in China

Gelonghui, May 9, 丨 Quanxin Bio-B (02509.HK) announced that on May 9, 2024, the humanized IgG1 monoclonal antibody Qx013n independently developed by the company obtained a new drug clinical trial license (acceptance number: CXSL2400165) from the China National Drug Administration Drug Evaluation Center for the treatment of chronic spontaneous urticaria (CSU). Qx013n is China's first biopharmaceutical candidate targeting c-Kit. CSU is a common chronic inflammatory skin disease characterized by spontaneous skin lumps and/or angioedema, which lasts longer than

Gelonghui FinanceMay 9 09:06 ET